AI Article Synopsis
- The study aimed to evaluate the effectiveness and tolerability of gepirone in extended-release form (gepirone-ER) compared to a placebo in patients with major depressive disorder.
- Participants aged 18 to 70 with moderate-to-severe depression were randomly assigned to receive either gepirone-ER or placebo for 56 days, and assessments were made at various weeks.
- Results showed that gepirone-ER led to significantly greater improvements in depression scores and responder rates than placebo, and it was generally well tolerated with minimal adverse effects.
Article Abstract
Objective: To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder.
Method: Patients aged 18 to 70 years were eligible if they satisfied DSM-IV criteria for moderate-to-severe major depressive disorder and had a baseline 17-item Hamilton Rating Scale for Depression (HAM-D-17) score > or = 20. After a 4- to 7-day placebo washout period, patients were randomly assigned to receive either placebo (N = 106) or gepirone-ER (20-80 mg/day) (N = 103) for 56 days. Assessments were done at weeks 1-4, 6, and 8.
Results: Mean change from baseline in HAM-D-17 score within the intent-to-treat group (gepirone, N = 101; placebo, N = 103) was significantly greater with gepirone-ER than placebo at weeks 3 (p =.013) and 8 (p =.018). Significantly (p <.05) more patients receiving gepirone-ER than placebo were HAM-D-17 responders at weeks 3 (33.7% vs. 18.8%, respectively) and 4 (38.6% vs. 24.8%, respectively) and HAM-D-17 remitters at weeks 6 (24.8% vs. 13.9%, respectively) and 8 (28.7% vs. 14.9%, respectively). Mean change from baseline for HAM-D-25 total score was significantly (p < pr =.05) greater with gepirone-ER at all assessments except week 6. The proportion of HAM-D-25 responders was significantly greater (p < or =.05) with gepirone-ER at weeks 3 and 8. Gepirone-ER was well tolerated: 9.8% of the gepirone-ER group and 2.8% of the placebo group discontinued due to adverse events. Common adverse events were considered mild and included dizziness, nausea, and insomnia. Gepirone-ER did not differ statistically compared with placebo in weight gain or sedation. Furthermore, preliminary evidence suggested that gepirone-ER may not be associated with sexual dysfunction. No serious adverse events occurred in gepirone-treated patients.
Conclusion: Gepirone-ER is effective for the short-term treatment of major depressive disorder and is well tolerated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Are breast cancer patients with low distress at diagnosis at risk of psychological symptoms later in their disease trajectory? Considerations for when to screen for distress.
Acta Oncol
January 2025
Psychological Aspects of Cancer, Cancer Survivorship, The Danish Cancer Institute, Copenhagen, Denmark.
Introduction: To target psychological support to cancer patients most in need of support, screening for psychological distress has been advocated and, in some settings, also implemented. Still, no prior studies have examined the appropriate 'dosage' and whether screening for distress before cancer treatment may be sufficient or if further screenings during treatment are necessary. We examined the development in symptom trajectories for breast cancer patients with low distress before surgery and explored potential risk factors for developing burdensome symptoms at a later point in time.
View Article and Find Full Text PDFSubclinical depressive symptoms and job stress differentially impact memory in working and retired older adults.
Sci Rep
January 2025
Department of Psychological Sciences, Rice University, 6100 Main St, Houston, TX, 77005, USA.
Retirement has been associated with cognitive decline beyond normal age-related decline. However, there are many individual differences in retirement that can influence cognition. Subclinical depressive symptoms are common in late life and are associated with general memory decline and a bias towards remembering negative events (i.
View Article and Find Full Text PDFNeuromonitoring-guided anesthesia depth versus four-minute anesthesia-to-stimulation time interval in electroconvulsive therapy for depressive disorders - A single-blinded, prospective, randomized and controlled study.
J Affect Disord
January 2025
Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria. Electronic address:
Background: Anesthesia depth influences seizure quality in patients undergoing electroconvulsive therapy (ECT). EEG-based neuromonitoring has been shown to detect adequate anesthesia depth for ECT. Anesthesia depth-guided ECT management may therefore be a reliable alternative to the predetermined anesthesia-to-stimulation time interval.
View Article and Find Full Text PDFSpecific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex.
J Affect Disord
January 2025
Department of Medicine and Surgery, Kore University of Enna, Italy; Oasi Research Institute-IRCCS, Troina, Italy. Electronic address:
Background: Clinical predictors of treatment-resistant depression could improve treatment strategies. Depressive symptom profiles at baseline are potential outcome predictors, but little evidence is available, and sex-specific profiles have been scarcely investigated.
Methods: Baseline symptom scores of 1294 patients with major depressive disorder were assessed by the Montgomery-Åsberg depression rating scale (MADRS) as part of a multicenter study by the "Group for the Studies of Resistant Depression".
Depression and Anxiety Disorders among Persons with Type 2 Diabetes Mellitus in a Tertiary Hospital in Zaria, Nigeria.
West Afr J Med
September 2024
Mental Health Unit, Federal Medical Centre, Jabi, Abuja.
Background: Depression and anxiety disorders frequently co-occur with Type 2 Diabetes Mellitus, leading to poor glycaemic control and quality of life through complex biopsychosocial mechanisms. A dual diagnosis of chronic medical and mental health conditions reduces the probability of early recognition and intervention for either. This study was aimed at assessing the prevalence and correlates of depression and anxiety disorders among persons with Type 2 Diabetes Mellitus in a tertiary hospital in North-West Nigeria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!